0001104659-21-132984.txt : 20211102 0001104659-21-132984.hdr.sgml : 20211102 20211102160201 ACCESSION NUMBER: 0001104659-21-132984 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211102 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211102 DATE AS OF CHANGE: 20211102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZYNEX INC CENTRAL INDEX KEY: 0000846475 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 870403828 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38804 FILM NUMBER: 211371108 BUSINESS ADDRESS: STREET 1: 9655 MAROON CIRCLE CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: (800)-495-6670 MAIL ADDRESS: STREET 1: 9655 MAROON CIRCLE CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20050812 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20040120 FORMER COMPANY: FORMER CONFORMED NAME: FOX RIVER HOLDINGS INC DATE OF NAME CHANGE: 20031126 8-K 1 tm2131612d1_8k.htm 8-K
0000846475 false 0000846475 2021-11-02 2021-11-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 2, 2021

 

Zynex, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

       Nevada        001-38804 90-0275169
(State or other jurisdiction
 of incorporation)		 Commission File
Number

(I.R.S. Employer Identification

number)

  

9655 Maroon Circle, Englewood, CO 80112

(Address of principal executive offices)  (Zip Code)

 

Registrant's telephone number, including area code:  (800) 495-6670

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Ticker symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per share ZYXI The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

ITEM 2.02Results of Operations and Financial Condition

 

On November 2, 2021, Zynex, Inc. issued a press release announcing certain results for the third quarter of 2021. The full text of the press release is furnished herewith as Exhibit 99.1.

 

The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

 

ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS

 

d) Exhibits. The following exhibits are filed with this report.

 

Exhibit No. Description
99.1 Zynex, Inc. Press Release dated November 2, 2021
104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: November 2, 2021 ZYNEX, INC.
   
  /s/ Dan Moorhead
  Dan Moorhead
  Chief Financial Officer
   

 

 

 EX-99.1 2 tm2131612d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

Zynex Announces 2021 Third Quarter Earnings

 

• 2021 Third Quarter  
   
  o Revenue increased 74% year over year to $34.8 million
   
  o Orders increased 70%
   
  o Record net income of $6.1 million; Diluted EPS $0.17
   
  o Adjusted EBITDA $9.3 million

  

 

ENGLEWOOD, CO – November 2, 2021 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its third quarter ended September 30, 2021.

 

Third Quarter Financial Results Summary:

 

For the third quarter, the Company reported net revenue of $34.8 million, a 74% increase over the third quarter of 2020. Gross margins were 80% in the third quarter of 2021 and net income was $6.1 million.

 

Adjusted EBITDA was $9.3 million in the third quarter of 2021.

 

As of September 30, 2021, the Company had working capital of $59.6 million a 13% increase compared to June 30, 2021. Cash on hand was $35.4 million at the end of the third quarter. Cash increased by more than 9% during the quarter due to the Company posting record profitability.

 

President and CEO Commentary:

 

Thomas Sandgaard, CEO said: “I am excited about our order growth in the third quarter of 70% which we expect will continue to drive increasing revenue in 2021 and 2022. In the third quarter, we posted revenue of $34.8 million and net income of $6.1 million, both amounts are the highest in the history of the Company. We are pleased with our continued revenue growth and the related profitability as we continue to leverage the investments we’ve made in our sales organization over the past couple of years. There is a sizeable pain management market in the U.S. and worldwide that can benefit from our products and we are just scratching the surface of the addressable market.

 

In our Monitoring Solutions Division, our team just returned from the American Society of Anesthesiologists annual conference where we received positive feedback from clinicians and institutions on our CM-1500 Blood and Fluid Monitor. We expect to submit our next generation CM-1600 for FDA clearance within the next ninety days as our engineering team is making great progress.

 

We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids.”

 

Fourth Quarter and Full Year 2021 Guidance:

 

The estimated range for fourth quarter revenue is between $40.0 and $43.0 million with Adjusted EBITDA between $9.0 and $10.0 million. The revenue estimate is approximately 56% to 68% above 2020 fourth quarter revenue of $25.6 million. 

 

Full year 2021 revenue is estimated between $130.0 and $133.0 million with Adjusted EBITDA between $22.7 and $23.7 million. The full year revenue estimate is approximately 62% to 66% above 2020 revenue of $80.1 million. Full year Adjusted EBITDA growth in 2021 is approximately 66% to 73% compared to 2020.

 

 

 

 

Conference Call and Webcast Details:

 

Tuesday, November 2, 2021 at 2:15 p.m. MT / 4:15 p.m. ET

 

To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast:

 

https://www.webcaster4.com/Webcast/Page/1487/43407

 

US PARTICIPANT DIAL IN (TOLL FREE): 1-844-825-9790
INTERNATIONAL DIAL IN: 1-412-317-5170
Canada Toll Free: 1-855-669-9657

 

Non-GAAP Financial Measures

 

Zynex reports its financial results in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition, the Company is providing in this news release financial information in the form of Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, other income/expense, stock compensation, restructuring and non-cash lease charges). Management believes these non-GAAP financial measures are useful to investors and lenders in evaluating the overall financial health of the Company in that they allow for greater transparency of additional financial data routinely used by management to evaluate performance. Adjusted EBITDA can be useful for investors or lenders as an indicator of available earnings. Non-GAAP financial measures should not be considered in isolation from or as an alternative to the financial information prepared in accordance with GAAP.

 

About Zynex, Inc. 


Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a fluid monitoring system for use in hospitals and surgery centers. For additional information, please visit: www.zynex.com.

 

Safe Harbor Statement

 

This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

 

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2020 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

 

 

 

 

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

Contact: Zynex, Inc. (800) 495-6670

 

Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

 

 
 

 

ZYNEX, INC.

CONSOLIDATED BALANCE SHEETS

(AMOUNTS IN THOUSANDS)

(unaudited)

 

   September 30,   December 31, 
   2021   2020 
ASSETS          
Current assets:          
Cash  $35,368   $39,173 
Accounts receivable, net   24,234    13,837 
Inventory, net   9,154    8,635 
Prepaid expenses and other   1,102    1,378 
                                               Total current assets   69,858    63,023 
           
Property and equipment, net   2,253    1,925 
Operating lease asset   17,234    5,993 
Finance lease asset   418    321 
Deposits   584    347 
Deferred income taxes   376    566 
                                               Total assets  $90,723   $72,175 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable and accrued expenses   2,669    4,717 
Operating lease liability   2,416    2,051 
Finance lease liability   115    77 
Income taxes payable   1,577    280 
Accrued payroll and related taxes   3,515    2,992 
                                              Total current liabilities   10,292    10,117 
Long-term liabilities:          
Operating lease liability   16,701    4,920 
Finance lease liability   347    283 
                                              Total liabilities   27,340    15,320 
           
Stockholders' equity:          
Common stock   37    36 
Additional paid-in capital   38,220    37,235 
Treasury Stock   (6,513)   (3,846)
Retained earnings   31,639    23,430 
                                              Total stockholders' equity   63,383    56,855 
                                              Total liabilities and stockholders' equity  $90,723   $72,175 

 

 

 

  

ZYNEX, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

 

   For the Three Months Ended September 30,   For the Nine Months Ended September 30, 
   2021   2020   2021   2020 
NET REVENUE                    
Devices  $9,071   $5,301   $23,264   $13,026 
Supplies   25,715    14,725    66,671    41,491 
Total net revenue   34,786    20,026    89,935    54,517 
                     
COSTS OF REVENUE AND OPERATING EXPENSES                    
Costs of revenue - devices and supplies   6,837    4,296    19,990    11,758 
Sales and marketing   13,083    9,425    40,662    21,817 
General and administrative   6,820    4,896    18,503    12,990 
Total costs of revenue and operating expenses   26,740    18,617    79,155    46,565 
                     
Income from operations   8,046    1,409    10,780    7,952 
                     
Other expense                    
   Interest expense   (18)   (5)   (72)   (14)
Other expense, net   (18)   (5)   (72)   (14)
                     
Income from operations before income taxes   8,028    1,404    10,708    7,938 
  Income tax expense   1,921    71    2,499    651 
Net Income  $6,107   $1,333   $8,209   $7,287 
                     
Net income per share:                    
Basic  $0.18   $0.04   $0.24   $0.22 
                     
Diluted  $0.17   $0.04   $0.23   $0.21 
                     
Weighted average basic shares outstanding   34,768    34,486    34,805    33,564 
Weighted average diluted shares outstanding   35,493    35,476    35,583    34,715 

 

 

 

 

ZYNEX, INC.

Reconciliation of GAAP to Non-GAAP Measures

(in thousands)

(unaudited)

 

   For the Three Months Ended September 30,   For the Nine Months Ended September 30, 
   2021   2020   2021   2020 
Adjusted EBITDA:                    
Net income  $6,107   $1,333   $8,209   $7,287 
Depreciation and Amortization*   201    305    711    470 
Stock-based compensation expense   532    730    1,041    1,806 
Restructuring/severance**   -    -    318    - 
   Interest expense and other, net   18    5    72    14 
   Non-cash lease expense ***   553    -    856    - 
   Income tax expense   1,921    71    2,499    651 
Adjusted EBITDA  $9,332   $2,444   $13,706   $10,228 
% of Net Revenue   27%   12%   15%   19%

 

* Depreciation does not include amounts related to units on lease to third parties which are depreciated and included in cost of goods sold

** Severance of former COO Giusseppe Papandrea which was fully expensed in Q1-2021

*** Amount expensed on new company headquarters on which no payments are due until 2022

  

 

 

 

 

 

 

 EX-101.SCH 3 zyxi-20211102.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 zyxi-20211102_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 zyxi-20211102_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2131612d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000846475 2021-11-02 2021-11-02 iso4217:USD shares iso4217:USD shares 0000846475 false 8-K 2021-11-02 Zynex, Inc. NV 001-38804 90-0275169 9655 Maroon Circle Englewood CO 80112 800 495-6670 false false false false Common Stock, $0.001 par value per share ZYXI NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 02, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 02, 2021
Entity File Number 001-38804
Entity Registrant Name Zynex, Inc.
Entity Central Index Key 0000846475
Entity Tax Identification Number 90-0275169
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 9655 Maroon Circle
Entity Address, City or Town Englewood
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80112
City Area Code 800
Local Phone Number 495-6670
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol ZYXI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://zynexmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2131612d1_8k.htm tm2131612d1_ex99-1.htm zyxi-20211102.xsd zyxi-20211102_lab.xml zyxi-20211102_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2131612d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2131612d1_8k.htm" ] }, "labelLink": { "local": [ "zyxi-20211102_lab.xml" ] }, "presentationLink": { "local": [ "zyxi-20211102_pre.xml" ] }, "schema": { "local": [ "zyxi-20211102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "zyxi", "nsuri": "http://zynexmed.com/20211102", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2131612d1_8k.htm", "contextRef": "From2021-11-02to2021-11-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://zynexmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2131612d1_8k.htm", "contextRef": "From2021-11-02to2021-11-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://zynexmed.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-132984-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-132984-xbrl.zip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end